Open AccessCost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan
Author(s) -
Kazutoshi Tokunaga,
Chihiro Suzuki,
Miyuki Hasegawa,
Ikuo Fujimori
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s297680
Subject(s) - medicine , regimen , helicobacter pylori , clarithromycin , proton pump inhibitor , subgroup analysis , body mass index , meta analysis
Cost-benefit is an important consideration for Helicobacter pylori ( H. pylori) eradication in Japan, where 1.5 million patients were reported to receive first-line eradication annually. This study aimed to identify the optimal cost-saving triple therapy regimen for H. pylori eradication in Japan.